
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3793086/publications.pdf Version: 2024-02-01



Ζινλ Κιρκλιι

#	Article	IF	CITATIONS
1	Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology, 2005, 66, 4-34.	1.0	825
2	2004 WHO Classification of the Renal Tumors of the Adults. European Urology, 2006, 49, 798-805.	1.9	728
3	EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin. European Urology, 2016, 69, 60-69.	1.9	445
4	Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. European Urology, 2010, 57, 766-773.	1.9	347
5	Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group. European Urology, 2009, 55, 1269-1277.	1.9	213
6	2009 update on the classification of renal epithelial tumors in adults. International Journal of Urology, 2009, 16, 432-443.	1.0	207
7	Transitional cell carcinoma of the ureter and renal pelvis. Critical Reviews in Oncology/Hematology, 2003, 47, 155-169.	4.4	193
8	Positive Surgical Margins After Nephron-Sparing Surgery. European Urology, 2012, 61, 757-763.	1.9	186
9	Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States. Kidney International, 2013, 83, 479-486.	5.2	170
10	Contemporary Management of Small Renal Masses. European Urology, 2011, 60, 501-515.	1.9	164
11	A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. European Urology, 2007, 52, 658-662.	1.9	144
12	Histologic Grading of Noninvasive Papillary Urothelial Neoplasms. European Urology, 2007, 51, 889-898.	1.9	131
13	A Critical Analysis of the Actual Role of Minimally Invasive Surgery and Active Surveillance for Kidney Cancer. European Urology, 2010, 57, 223-232.	1.9	130
14	ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. European Urology, 2011, 60, 684-690.	1.9	125
15	The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urology, 2014, 14, 57.	1.4	123
16	Toxicities of Targeted Therapy and Their Management in Kidney Cancer. European Urology, 2011, 59, 526-540.	1.9	119
17	Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1305-1312.	4.5	106
18	Neuroendocrine tumours of the urinary system and male genital organs: clinical significance. BJU International, 2009, 103, 1464-1470.	2.5	94

#	Article	IF	CITATIONS
19	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. European Urology, 2010, 58, 819-828.	1.9	89
20	Prognostic and Therapeutic Impact of the Histopathologic Definition of Parenchymal Epithelial Renal Tumors. European Urology, 2010, 58, 655-668.	1.9	84
21	Secondary neoplasms of the urinary system and male genital organs. BJU International, 2009, 104, 770-776.	2.5	72
22	Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. European Urology, 2006, 50, 530-534.	1.9	70
23	Evidence of the Impact of Diet, Fluid Intake, Caffeine, Alcohol and Tobacco on Lower Urinary Tract Symptoms: A Systematic Review. Journal of Urology, 2017, 198, 1010-1020.	0.4	66
24	Effect of Tamsulosin on Passage of Symptomatic Ureteral Stones. JAMA Internal Medicine, 2018, 178, 1051.	5.1	65
25	Urinary Stone Disease: Progress, Status, and Needs. Urology, 2015, 86, 651-653.	1.0	63
26	Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined Therapy. Journal of Urology, 2014, 191, 1828-1834.	0.4	61
27	Reproducibility of the 1998 World Health Organization/International Society of Urologic Pathology classification of papillary urothelial neoplasms of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2003, 443, 734-740.	2.8	60
28	Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU International, 2008, 102, 1369-1374.	2.5	56
29	Basic Research in Kidney Cancer. European Urology, 2011, 60, 622-633.	1.9	55
30	Recent advances in kidney cancer and metastatic disease. BJU International, 2001, 88, 818-824.	2.5	54
31	Risk Factors for Mucosal Prostatic Urethral Involvement in Superficial Transitional Cell Carcinoma of the Bladder. European Urology, 2005, 48, 760-763.	1.9	52
32	Urological Aspects of Behcet's Disease. British Journal of Urology, 1991, 67, 638-639.	0.1	50
33	Effectiveness of Extracorporeal Shockwave Lithotripsy in the Management of Stone-Bearing Horseshoe Kidneys. Journal of Endourology, 1996, 10, 13-15.	2.1	50
34	Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study. Journal of Urology, 2018, 199, 1023-1031.	0.4	48
35	Significance of COX-2 expression in human renal cell carcinoma. Urology, 2004, 64, 1116-1120.	1.0	43
36	Pediatric Urinary Stone Disease in the United States: The Urologic Diseases in America Project. Urology, 2019, 129, 180-187.	1.0	43

#	Article	IF	CITATIONS
37	Serum Ferritin as a Clinical Markerfor Renal Cell Carcinoma: Influenc e of Tumor Size and Volume. Urologia Internationalis, 1999, 62, 21-25.	1.3	42
38	Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guérin and with Bacillus Calmette-Guérin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993). European Urology, 2011, 59, 438-446.	1.9	42
39	Relationship Between Central Obesity, General Obesity, Overactive Bladder Syndrome and Urinary Incontinence Among Male and Female Patients Seeking Care for Their Lower Urinary Tract Symptoms. Urology, 2019, 123, 34-43.	1.0	42
40	Handling and Pathology Reporting of Renal Tumor Specimens. European Urology, 2004, 45, 437-443.	1.9	41
41	Symptoms of Lower Urinary Tract Dysfunction Research Network. Journal of Urology, 2016, 196, 146-152.	0.4	40
42	Unclassified renal cell carcinoma: a report of 56 cases. BJU International, 2012, 110, 786-793.	2.5	38
43	Tunica Vaginalis: an Aid in Hypospadias Surgery. British Journal of Urology, 1990, 65, 530-532.	0.1	37
44	Mental Health, Sleep and Physical Function in Treatment Seeking Women with Urinary Incontinence. Journal of Urology, 2018, 200, 848-855.	0.4	36
45	Primary renal lymphoma of mucosa-associated lymphoid tissue. Urology, 2003, 61, 463.	1.0	35
46	Prognostic significance of angiogenesis and immunoreactivity of cathepsin d and type IV collagen in high-grade stage T1 primary bladder cancer. Urology, 1999, 54, 50-55.	1.0	34
47	Prognostic Significance of Estrogen Receptor Expression in Superficial Transitional Cell Carcinoma of the Urinary Bladder. European Urology, 2002, 41, 342-345.	1.9	33
48	Are threeâ€day voiding diaries feasible and reliable? Results from the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) cohort. Neurourology and Urodynamics, 2019, 38, 2185-2193.	1.5	33
49	Significance of heat shock protein-27 expression in patients with renal cell carcinoma. Urology, 2004, 64, 474-478.	1.0	32
50	Place of Double-J Stents in Extracorporeal Shock Wave Lithotripsy. European Urology, 1993, 23, 460-462.	1.9	31
51	Ferritin: A Tumor Marker Expressed by Renal Cell Carcinoma. European Urology, 1995, 28, 131-134.	1.9	31
52	Can mycoplasma-mediated oncogenesis be responsible for formation of conventional renal cell carcinoma?. Urology, 2005, 65, 411-414.	1.0	31
53	Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project. Journal of Urology, 2020, 203, 171-178.	0.4	30
54	What Does the Urologist Expect from the Pathologist (and What Can the Pathologists Give) in Reporting on Adult Kidney Tumour Specimens?. European Urology, 2007, 51, 1194-1201.	1.9	29

#	Article	IF	CITATIONS
55	Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?. BJU International, 2009, 103, 1058-1063.	2.5	29
56	Renal Effects of Carbon Dioxide Insufflation in Rabbit Pneumoretroperitoneum Model. Journal of Endourology, 1998, 12, 367-370.	2.1	28
57	METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA: SUBCELLULAR LOCALIZATION AND PROGNOSTIC SIGNIFICANCE. Journal of Urology, 2001, 165, 1710-1713.	0.4	28
58	Current management of renal cell carcinoma and targeted therapy. Urology Journal, 2006, 3, 1-14.	0.4	28
59	Silent Testicular Metastasis from Carcinoma of the Prostate. British Journal of Urology, 1990, 66, 205-207.	0.1	27
60	Epidemiological Case-Control Study on the Etiology of Bladder Cancer in Turkey. European Urology, 1990, 17, 23-26.	1.9	27
61	Critical Evaluation of the Prostate from Cystoprostatectomies for Bladder Cancer: Insights from a Complete Sampling with the Whole Mount Technique. European Urology, 2009, 55, 1305-1309.	1.9	27
62	Multigene Methylation Analysis of Conventional Renal Cell Carcinoma. Urologia Internationalis, 2009, 83, 107-112.	1.3	27
63	Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses. Journal of Urology, 2019, 202, 880-889.	0.4	27
64	Quality control of radical prostatectomy. European Journal of Cancer, 2001, 37, 884-891.	2.8	26
65	Renal cell carcinoma: new prognostic factors?. Current Opinion in Urology, 2003, 13, 433-438.	1.8	25
66	International Consultation on Urologic Diseases and the European Association of Urology International Consultation on Locally Advanced Renal Cell Carcinoma. European Urology, 2011, 60, 673-683.	1.9	25
67	Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered) Tj ETQq1 1 0.7 Und Fur Klinische Medizin, 2011, 458, 659-664.	784314 rg 2.8	BT /Overlock 25
68	Long-Term Effects of Doxazosin, Finasteride and Combination Therapy on Quality of Life in Men with Benign Prostatic Hyperplasia. Journal of Urology, 2013, 190, 187-193.	0.4	25
69	Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder. Translational Andrology and Urology, 2015, 4, 524-33.	1.4	25
70	The Effect of Extracorporeal Electromagnetic Shock Waves on the Morphology and Contractility of Rabbit Ureter. Journal of Urology, 1995, 154, 1939-1943.	0.4	23
71	1,25 Dihydroxyvitamin D Receptor Expression in Superficial Transitional Cell Carcinoma of the Bladder: A Possible Prognostic Factor?. European Urology, 2005, 47, 52-57.	1.9	23
72	Expression of COX-2 in Normal and Pyelonephritic Kidney, Renal Intraepithelial Neoplasia, and Renal Cell Carcinoma. European Urology, 2006, 50, 92-97.	1.9	23

#	Article	IF	CITATIONS
73	Joint Appraisal of the Radical Prostatectomy Specimen by the Urologist and the Uropathologist: Together, We Can Do It Better. European Urology, 2009, 56, 951-955.	1.9	23
74	Inverted (Endophytic) Noninvasive Lesions and Neoplasms of the Urothelium: The Cinderella Group Has Yet to Be Fully Exploited. European Urology, 2011, 59, 225-230.	1.9	23
75	Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. European Urology, 2013, 64, 865-872.	1.9	23
76	Bellini duct (collecting duct) carcinoma of the kidney. Urology, 1996, 47, 921-923.	1.0	22
77	Does angiogenesis predict recurrence in superficial transitional cell carcinoma of the bladder?. Urology, 2001, 57, 895-899.	1.0	22
78	Expression of p53 and mdm2 and Their Significance in Recurrence of Superficial Bladder Cancer. Pathology Research and Practice, 2003, 199, 323-328.	2.3	22
79	Clinical Aspects of Renal Cell Carcinoma. EAU Update Series, 2003, 1, 189-196.	0.5	22
80	Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder. Journal of Cancer Research and Clinical Oncology, 2004, 130, 122-125.	2.5	22
81	Prediction of Prostatic Involvement by Urothelial Carcinoma in Radical Cystoprostatectomy for Bladder Cancer. Urology, 2009, 74, 385-390.	1.0	22
82	Advancing a Comprehensive Approach to the Study of Lower Urinary Tract Symptoms. Journal of Urology, 2016, 196, 1342-1349.	0.4	22
83	A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Indexâ€29 (LURN SIâ€29) questionnaire. Neurourology and Urodynamics, 2019, 38, 1751-1759.	1.5	22
84	99mTc-MIBI scintigraphy in metastatic renal cell carcinoma: clinical validation of the relationship between99mTc-MIBI uptake and P-alvcoprotein expression in tumour tissue. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 976-979.	2.1	21
85	Tubular dysplasia and carcinoma in situ: precursors of renal cell carcinoma. Urology, 1999, 53, 684-689.	1.0	21
86	Prevalence and Characteristics of Urinary Incontinence in a Treatment Seeking Male Prospective Cohort: Results from the LURN Study. Journal of Urology, 2018, 200, 397-404.	0.4	21
87	A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. Journal of Urology, 2020, 203, 164-170.	0.4	21
88	Are Obstructing Ureteral Stones More Difficult to Treat with Extracorporeal Electromagnetic Shock Wave Lithotripsy?*. Journal of Endourology, 1993, 7, 277-279.	2.1	20
89	Precancerous Lesions in the Kidney. Scandinavian Journal of Urology and Nephrology, 2000, 34, 136-165.	1.4	20
90	Symptom Based Clustering of Women in the LURN Observational Cohort Study. Journal of Urology, 2018, 200, 1323-1331.	0.4	20

#	Article	IF	CITATIONS
91	Precancerous Lesions in the Kidney. Scandinavian Journal of Urology and Nephrology, 2000, 34, 136-165.	1.4	20
92	Prognostic significance of nuclear morphometry in renal cell carcinoma. BJU International, 2002, 90, 20-25.	2.5	19
93	Prevention of Urinary Stones With Hydration (PUSH): Design and Rationale of a Clinical Trial. American Journal of Kidney Diseases, 2021, 77, 898-906.e1.	1.9	19
94	Is Magnetic Resonance Imaging Necessary in the Staging of Prostate Cancer?. Urologia Internationalis, 1998, 61, 227-231.	1.3	18
95	Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma. International Journal of Urology, 2001, 8, 697-703.	1.0	18
96	Conservative Management of Mucosal Prostatic Urethral Involvement in Patients with Superficial Transitional Cell Carcinoma of the Bladder. European Urology, 2004, 45, 465-470.	1.9	18
97	Echo Contrast-Enhanced Power Doppler Ultrasonography for Assessment of Angiogenesis in Renal Cell Carcinoma. Journal of Ultrasound in Medicine, 2005, 24, 747-753.	1.7	18
98	Cross-Sectional and Longitudinal Associations of Sexual Function with Lower Urinary Tract Symptoms in Men with Benign Prostatic Hyperplasia. Journal of Urology, 2015, 193, 231-238.	0.4	18
99	Cysts of the Prostate, Seminal Vesicles and Diverticulum of the Ejaculatory Ducts. European Urology, 1991, 20, 77-80.	1.9	17
100	Renal Cell Carcinoma with Gallbladder Metastasis. International Journal of Urology, 1998, 5, 288-290.	1.0	17
101	Significance of Tissue Laminin P <sub>1</sub> Elastase and Fibronectin Levels in Transitional Cell Carcinoma of the Bladder. European Urology, 2001, 39, 292-299.	1.9	17
102	Reasons for Seeking Clinical Care for Lower Urinary Tract Symptoms: A Mixed Methods Study. Journal of Urology, 2018, 199, 528-535.	0.4	17
103	National Trends in the Surgical Management of Urinary Incontinence among Insured Women, 2004 to 2013: The Urologic Diseases in America Project. Journal of Urology, 2020, 203, 365-371.	0.4	17
104	Urothelial Tumours of the Upper Urinary Tract. British Journal of Urology, 1989, 64, 18-24.	0.1	16
105	Expression of Cathepsin D in Bladder Carcinoma: Correlation with Pathological Features and Serum Cystatin C Levels. Tumori, 2006, 92, 230-235.	1.1	16
106	Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen?. European Urology, 2009, 56, 272-274.	1.9	16
107	Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence. Neurourology and Urodynamics, 2018, 37, 2586-2596.	1.5	16
108	Investigation of p53, c-erbB-2, PCNA immunoreactivity, DNA content, AgNOR and apoptosis in bladder carcinoma as prognostic parameters. Cancer Letters, 1998, 126, 143-148.	7.2	15

#	Article	IF	CITATIONS
109	Effects of finasteride on the vascular surface density, number of microvessels and vascular endothelial growth factor expression of the rat prostate. International Urology and Nephrology, 2006, 38, 275-280.	1.4	15
110	A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate. Journal of Urology, 2007, 178, 2331-2336.	0.4	15
111	Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on longâ€ŧerm use. BJU International, 2011, 107, 1722-1732.	2.5	15
112	The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms. Journal of Urology, 2019, 201, 1177-1183.	0.4	15
113	Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?. Journal of Urology, 2019, 202, 770-778.	0.4	15
114	Patient Characteristics Associated with More Bother from Lower Urinary Tract Symptoms. Journal of Urology, 2019, 202, 585-591.	0.4	15
115	Unusual Metastases of Renal Cell Carcinoma. Urologia Internationalis, 1987, 42, 316-317.	1.3	14
116	Amiodarone-Induced Sterile Epididymitis. Urologia Internationalis, 1988, 43, 372-373.	1.3	14
117	Volume-weighted mean nuclear volume in renal cell carcinoma. Urology, 1998, 52, 44-47.	1.0	14
118	Testis sparing surgery for the treatment of a sequential bilateral testicular germ cell tumor. International Journal of Urology, 2001, 8, 710-712.	1.0	14
119	Prevalence, subtypes, and correlates of nocturia in the symptoms of Lower Urinary Tract Dysfunction Research Network cohort. Neurourology and Urodynamics, 2020, 39, 1098-1107.	1.5	14
120	Open Partial Nephrectomy in the Management of Small Renal Masses. Advances in Urology, 2008, 2008, 1-7.	1.3	13
121	Poor clinical guideline adherence and inappropriate testing for incident lower urinary tract symptoms associated with benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 2022, 25, 269-273.	3.9	13
122	Prostatic carcinoma presenting with painless parotid mass. Urology, 1995, 46, 406-407.	1.0	12
123	Chairmen's Summary. Scandinavian Journal of Urology and Nephrology, 2008, 42, 7-11.	1.4	12
124	Ablative therapies in the treatment of small renal tumors: How far from standard of care?. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 251-259.	1.6	12
125	Quality of Acute Care for Patients With Urinary Stones in the United States. Urology, 2015, 86, 914-921.	1.0	12
126	Ignificance of serum lam1nin P1 values in patients with transitional cell carcinoma of the bladder. Urology, 1996, 48, 496-500.	1.0	11

#	Article	lF	CITATIONS
127	Intermittent Androgen Deprivation for Locally Advanced Prostate Cancer. Oncology, 2003, 65, 24-28.	1.9	11
128	Premalignant lesions of the kidney share the same genetics changes as conventional renal cell carcinoma. World Journal of Urology, 2004, 22, 120-3.	2.2	11
129	Influence of Serotonin on the Human Ureter: An in vitro Pharmacological Study. Urologia Internationalis, 1995, 55, 202-204.	1.3	10
130	Contractility Changes of the Deep Dorsal Penile Vein Due to Serotonin. Journal of Urology, 1997, 158, 234-237.	0.4	10
131	Genetic profiles in renal tumors. International Journal of Urology, 2010, 17, 6-19.	1.0	10
132	Comparison of Microvascularization in Diagnostic Needle Biopsies and Radical Prostatectomies in Prostate Carcinoma. European Urology, 1999, 35, 109-112.	1.9	9
133	RE: RECURRENT BILATERAL AMIODARONE INDUCED EPIDIDYMITIS. Journal of Urology, 1999, 162, 808-809.	0.4	9
134	Superficial Urothelial Cancer in the Prostatic Urethra. Scientific World Journal, The, 2006, 6, 2603-2610.	2.1	9
135	Targeted therapies and biological modifiers in urologic tumors: pathobiology and clinical implications. Seminars in Diagnostic Pathology, 2008, 25, 232-244.	1.5	9
136	Study to Enhance Understanding of Stent-Associated Symptoms: Rationale and Study Design. Journal of Endourology, 2021, 35, 761-768.	2.1	9
137	Symptom Based Clustering of Men in the LURN Observational Cohort Study. Journal of Urology, 2019, 202, 1230-1239.	0.4	9
138	HLA Antigens and Transitional Cell Carcinoma of the Bladder. Urologia Internationalis, 1990, 45, 75-77.	1.3	8
139	RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA. Journal of Urology, 1998, 159, 2076-2076.	0.4	8
140	PHARMACOLOGICAL ANALYSIS OF 5-HYDROXYTRYPTAMINE EFFECTS ON HUMAN ISOLATED URETER. Pharmacological Research, 1999, 39, 487-491.	7.1	8
141	Ondansetron versus diclofenac sodium in the treatment of acute ureteral colic: a double blind controlled trial. International Urology and Nephrology, 2001, 33, 315-319.	1.4	8
142	Active surveillance for small renal tumors: Have clinical concerns been addressed so far?. International Journal of Urology, 2013, 20, 356-361.	1.0	8
143	PNFLBA-04 RANDOMIZED CLINICAL TRIAL OF TREATMENT WITH TAMSULOSIN BEGUN IN THE EMERGENCY DEPARTMENT TO PROMOTE PASSAGE OF URINARY STONES. Journal of Urology, 2017, 197, .	0.4	8
144	Handling and Pathology Reporting of Adrenal Gland Specimens. European Urology, 2004, 45, 722-729.	1.9	7

#	Article	IF	CITATIONS
145	Lymphocytic vasculitis of the prostate transition zone. BJU International, 2012, 110, 1775-1780.	2.5	7
146	Design and challenges of a randomized clinical trial of medical expulsive therapy (tamsulosin) for urolithiasis in the emergency department. Contemporary Clinical Trials, 2017, 52, 91-94.	1.8	7
147	The LURN Research Network Neuroimaging and Sensory Testing (NIST) Study: Design, protocols, and operations. Contemporary Clinical Trials, 2018, 74, 76-87.	1.8	7
148	Accuracy of Patient Reported Stone Passage for Patients With Acute Renal Colic Treated in the Emergency Department. Urology, 2020, 136, 70-74.	1.0	7
149	Somatostatin receptor subtypes in hormone-refractory (castration-resistant) prostatic carcinoma. Asian Journal of Andrology, 2011, 13, 242-247.	1.6	7
150	The Role of Delay in Stage-Ill Testicular Tumors. European Urology, 1986, 12, 151-153.	1.9	6
151	Urothelial carcinoma of the bladder with trophoblastic differentiation: A case report. International Urology and Nephrology, 2004, 36, 529-531.	1.4	6
152	Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2?. Future Oncology, 2009, 5, 871-888.	2.4	6
153	Kidney cancer in the elderly. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 673-676.	1.6	6
154	A Novel Proteomics Approach to Identify Serum and Urinary Biomarkers and Pathways that Associate with Lower Urinary Tract Symptoms in Men and Women: Pilot Results of the Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Study. Urology, 2019, 129, 35-42.	1.0	6
155	Longitudinal changes in symptomâ€based female and male LUTS clusters. Neurourology and Urodynamics, 2020, 39, 393-402.	1.5	6
156	Genito-Urological Cancers in Elderly Patients. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 1391-1405.	1.7	6
157	Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors. Central European Journal of Urology, 2015, 68, 45-50.	0.3	6
158	Renal Cell Carcinoma: Overview. , 2008, , 263-280.		6
159	Primary signetâ€ring cell carcinoma of the bladder. British Journal of Urology, 1994, 73, 210-211.	0.1	5
160	The Distribution of Post-Void Residual Volumes in People Seeking Care in the Symptoms of Lower Urinary Tract Dysfunction Network Observational Cohort Study With Comparison to Asymptomatic Populations. Urology, 2019, 130, 22-28.	1.0	5
161	Patient demographic and psychosocial characteristics associated with 30â€day recall of selfâ€reported lower urinary tract symptoms. Neurourology and Urodynamics, 2020, 39, 1939-1948.	1.5	5
162	The motion: open partial nephrectomy is the standard of care for small resectable solid renal masses. European Urology, 2007, 51, 561-2; discussion 564.	1.9	5

ZIYA KIRKALI

#	Article	IF	CITATIONS
163	Quality of life impact and recovery after ureteroscopy and stent insertion: insights from daily surveys in STENTS. BMC Urology, 2022, 22, 53.	1.4	5
164	Testicular Microlithiasis Associated with Teratocarcinoma and Intratubular Germ Cell Neoplasia: A Case Report. International Journal of Urology, 1997, 4, 530-532.	1.0	4
165	Ganglion cells in the human prostate. Prostate Cancer and Prostatic Diseases, 2000, 3, 34-36.	3.9	4
166	Developments in Organ Preserving Treatments for Renal Cell Cancer: Open Surgery. European Urology Supplements, 2004, 3, 9-13.	0.1	4
167	The Motion: Cryotherapy is an Efficient Alternative for Kidney Cancer. European Urology, 2010, 57, 168-170.	1.9	4
168	Somatostatin receptor expression in prostate carcinoma: the urological pathologist's role in the era of personalised medicine. Pathology, 2013, 45, 93-96.	0.6	4
169	Relationship of symptom severity and bother in individuals seeking care for lower urinary tract symptoms. Neurourology and Urodynamics, 2020, 39, 2161-2170.	1.5	4
170	Does Respiratory Gating Improve Extracorporeal Shockwave Lithotripsy Results?. Journal of Endourology, 1994, 8, 329-330.	2.1	3
171	Effect of Extracorporeal Shockwave Lithotripsy on Plasma and Urine Endothelin Concentrations. Journal of Endourology, 1996, 10, 325-327.	2.1	3
172	Expression of PS2 Protein and Its Relation with the Ki–67 Proliferative Indices and Tumor Recurrence in Superficial Bladder Carcinomas. European Urology, 2001, 40, 163-168.	1.9	3
173	RE: THE PATIENT WITH CHRONIC EPIDIDYMITIS: CHARACTERIZATION OF AN ENIGMATIC SYNDROME. Journal of Urology, 2002, 168, 2132-2133.	0.4	3
174	The Future of Oncological Urology in Europe: Are we Prepared?. European Urology, 2006, 49, 11-12.	1.9	3
175	Will We Be Able to "Cure―Metastatic Renal Cell Carcinoma Like We Cure Testicular Tumours?. European Urology, 2008, 54, 712-714.	1.9	3
176	Re: Matthias May, Sabine Brookman-Amissah, Jan Roigas, et al. Prognostic Accuracy of Individual Uropathologists in Noninvasive Urinary Bladder Carcinoma: A Multicentre Study Comparing the 1973 and 2004 World Health Organisation Classifications. Eur Urol 2010;57:850–8. European Urology, 2010, 58, e7.	1.9	3
177	716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB. Journal of Urology, 2011, 185, .	0.4	3
178	Research Needs to Understand Self-Management of Lower Urinary Tract Symptoms: Summary of NIDDK Workshop. Journal of Urology, 2018, 199, 1408-1410.	0.4	3
179	National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project. Urology, 2021, 150, 86-91.	1.0	3
180	A Prospective Survey of Surgical Approaches in Clinically Localized Renal Cell CarcinomaA Preliminary Attempt at Surgical Quality Control. UroOncology, 2002, 2, 169-174.	0.1	3

#	Article	IF	CITATIONS
181	Role of Transition Zone Index in the Prediction of Clinical Benign Prostatic Hyperplasia. Journal of Urological Surgery, 2016, 3, 114-118.	0.1	3
182	Blood Groups and Transitional Cell Carcinoma of the Upper Urinary Tract. European Urology, 1988, 14, 22-23.	1.9	2
183	Extracorporeal Electromagnetic Shock Wave Lithotripsy of Ureteric Stones in Situ. Journal of Endourology, 1992, 6, 411-412.	2.1	2
184	Re: Nephroureterectomy for Treating Upper Urinary Tract Transitional Cell Carcinoma. Time to Change the Treatment Paradigm?. European Urology, 2007, 51, 1141-1142.	1.9	2
185	Editorial Comment on: Prognostic Value of Renal Vein and Inferior Vena Cava Involvement in Renal Cell Carcinoma. European Urology, 2009, 55, 460.	1.9	2
186	Editorial Comment on: Predicting Occult Multifocality of Renal Cell Carcinoma. European Urology, 2010, 58, 126.	1.9	2
187	The Changing Face of Renal-Cell Carcinoma. Journal of Endourology, 2010, 24, 753-757.	2.1	2
188	NIH research opportunities for the prevention and treatment for chronic conditions. Translational Behavioral Medicine, 2018, 8, 509-514.	2.4	2
189	Analgesic and Opioid Use for Patients Discharged from the Emergency Department with Ureteral Stones. Journal of Endourology, 2021, 35, 1067-1071.	2.1	2
190	Advanced Tumors: Tumor Thrombus. , 2008, , 237-252.		2
191	Resolution of Hydronephrosis and Pain to Predict Stone Passage for Patients with Acute Renal Colic. Urology, 2021, , .	1.0	2
192	RENAL BOTRYOMYCOSIS MIMICKING RENAL CELL CARCINOMA. Journal of Urology, 1998, 159, 2076.	0.4	2
193	Do we need new patient reported measures to evaluate lower urinary tract dysfunction?. Indian Journal of Urology, 2016, 32, 91.	0.6	2
194	Androgen Receptors - A Method to Measure Functional Behaviour in Human Prostatic Cancer. European Urology, 1990, 17, 66-68.	1.9	1
195	Locally Recurrent Paratesticular Rhabdomyosarcoma Treated with Surgery and Radiotherapy. Urologia Internationalis, 1998, 60, 264-265.	1.3	1
196	Vertebral Fracture Associated with Shockwave Lithotripsy in a Patient with Granulomatous Spondylitis. Journal of Endourology, 2001, 15, 687-689.	2.1	1
197	Bone Mineral Density and Biochemical Markers of Bone in Patients With Idiopathic Hypercalciuria. , 2003, 13, 417-421.		1
198	Editorial Comment on: Results of Endoluminal Occlusion of the Inferior Vena Cava During Radical Nephrectomy and Thrombectomy. European Urology, 2008, 54, 783-784.	1.9	1

#	Article	IF	CITATIONS
199	PROGNOSTIC FACTORS IN PATIENTS WITH INTERMEDIATE AND HIGH RISK STAGE Ta T1 PAPILLARY CARCINOMA OF THE BLADDER TREATED WITH MAINTENANCE EPIRUBICIN OR MAINTENANCE BACILLUS CALMETTE-GUERIN. RESULTS OF EORTC GU GROUP STUDY 30911. Journal of Urology, 2008, 179, 586-586.	0.4	1
200	Prostate Cancer: New Insights into Minimal and Localised Disease: Active Surveillance. European Urology Supplements, 2009, 8, 718-720.	0.1	1
201	Reply to José I. Lopéz's Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Stage pT0 in Radical Prostatectomy with No Residual Carcinoma and with a Previous Positive Biopsy Conveys a Wrong Message to Clinicians and Patients: Why Is Cancer Not Present in the Radical Prostatectomy Specimen? Eur Urol 2009:56:272–4. European Urology. 2010. 57. e22-e23.	1.9	1
202	Management of advanced prostate cancer – new drugs. Acta Oncológica, 2011, 50, 137-140.	1.8	1
203	Experimental Pain and Auditory Sensitivity in Overactive Bladder Syndrome: A Symptoms of the Lower Urinary Tract Dysfunction Research Network (LURN) Study. Journal of Urology, 2022, 207, 161-171.	0.4	1
204	METALLOTHIONEIN EXPRESSION IN RENAL CELL CARCINOMA:. Journal of Urology, 2001, , 1710-1713.	0.4	1
205	The International Prostate Forum introduction and history. Asian Journal of Andrology, 2015, 17, 863.	1.6	1
206	Androgen receptors in TCC. Urology, 1987, 29, 674.	1.0	0
207	Ureteric perforation after ureteroscopy. Urology, 1987, 30, 595.	1.0	0
208	Cisplatin and Etoposide Chemotherapy in the Treatment of Adult Wilms' Tumor. Urologia Internationalis, 1996, 57, 108-109.	1.3	0
209	RE: URINARY TRACT CANCER AND HEREDITARY NONPOLYPOSIS COLORECTAL CANCER. Journal of Urology, 1999, 161, 926-926.	0.4	0
210	RE: Etiology of Spontaneous Perirenal Hemorrhage: A Meta-Analysis. Journal of Urology, 2003, 170, 548-548.	0.4	0
211	Beyond Skeletal-Related Events. European Urology Supplements, 2006, 5, 553-555.	0.1	0
212	Editorial: Superficial Bladder Cancer. Scientific World Journal, The, 2006, 6, 2646-2646.	2.1	0
213	Reply to Dr Özdemir's Letter to the Editor re: Burcin Tuna, Kutsal Yorukoglu, Mehtat Unlu, M. Ugur Mungan and Ziya Kirkali, Association of Mast Cells with Microvessel Density in Renal Cell Carcinomas. Eur Urol. 2006;50:530–34. European Urology, 2006, 50, 621-622.	1.9	0
214	Puigvert: A Man with a Vision—Nephron-Sparing Surgery 30 Years Ago in Europe. European Urology, 2006, 50, 175-185.	1.9	0
215	Editorial: Special Issue. Current Treatment of Localized Renal Cancer. Scientific World Journal, The, 2007, 7, 1046-1046.	2.1	0
216	Reply to Apostolos P. Labanaris et al's Letter to the Editor re: Ziya Kirkali and Hein Van Poppel. A Critical Analysis of Surgery for Kidney Cancer with Vena Cava Invasion. Eur Urol 2007;52:658–62. European Urology, 2007, 52, 1801-1802.	1.9	0

ZIYA KIRKALI

#	Article	IF	CITATIONS
217	Editorial Comment on: Preservation of Renal Function Following Partial or Radical Nephrectomy Using 24-Hour Creatinine Clearance. European Urology, 2008, 54, 151-152.	1.9	0
218	What is new in kidney cancer?. Expert Review of Anticancer Therapy, 2009, 9, 1753-1755.	2.4	0
219	Urologic oncology in southern Europe: Perceived problems and current plans. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 121-122. Reply to Tomasso Cai, Lorenzo Giuseppe Luciani and Gianni Malossini's Letter to the Editor re: Richard	1.6	0
220	J. Śylvester, Maurizio A. Brausi, Wim J. kirkels, et al. Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder. Eur Urol 2010;57:766–73.	1.9	0
221	1474 SEQUENTIAL CHEMO-IMMUNOTHERAPY WITH MITOMYCIN C (MMC) AND BACILLUS CALMETTE-GUERIN (BCG) VERSUS BCG ALONE IN PATIENTS WITH CARCINOMA IN SITU (CIS) OF THE URINARY BLADDER. RESULTS OF EORTC GU GROUP RANDOMIZED PHASE II STUDY 30993. Journal of Urology, 2010, 183, .	0.4	Ο
222	Reply to Kiril Trpkov, Asli Yilmaz' Letter to the Editor re: Rodolfo Montironi, Liang Cheng, Antonio Lopez-Beltran, et al. Original Gleason System Versus 2005 ISUP Modified Gleason System: The Importance of Indicating Which System Is Used in the Patient's Pathology and Clinical Reports. Eur Urol 2010;58:369–73. European Urology, 2011, 59, e7-e8.	1.9	0
223	Renal Cell Carcinoma: A Changing Paradigm With a Need for Consensus. European Urology, 2011, 60, 613-614.	1.9	Ο
224	Reply to Jérôme Verine's Letter to the Editor re: Rodolfo Montironi, Marina Scarpelli, Liang Cheng, et al. Immunoglobulin G4–related Disease in Genitourinary Organs: An Emerging Fibroinflammatory Entity Often Misdiagnosed Preoperatively as Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.11.056. European Urology, 2013, 64, e53-e54.	1.9	0
225	Can We Change Patient Behaviors to Improve Urological Health?. Journal of Urology, 2013, 190, 383-384.	0.4	0
226	PD39-01 SEXUAL FUNCTION ASSOCIATED WITH LOWER URINARY TRACT SYMPTOMS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA: MTOPS COHORT OF CROSS-SECTIONAL AND LONGITUDINAL DATA. Journal of Urology, 2015, 193, .	0.4	0
227	Editorial: Superficial Bladder Cancer. TSW Urology, 2006, 1, 44-44.	0.1	0
228	1728: A Novel Resectoscope for Transurethral Resection of Bladder Tumors and the Prostate. Journal of Urology, 2007, 177, 575-575.	0.4	0
229	Experience with Treatment of Nonseminomatous Germ Cell Tumors of Testis in Turkey. , 1985, , 263-268.		0
230	Re: Top cited articles in urology from Turkey. Turkish Journal of Urology, 2017, 43, 227-227.	1.3	0
231	Strengthening Research in Benign Urology: Dispelling Myths that Impede Success. Journal of Urology, 2019, 202, 42-44.	0.4	0